Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | HTR6 | P50406 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CALML3 | P27482 | 1/20 | 0.30 |
| ▸ | SDHA | P31040 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048619 | 0.81 | MAOA (0.48) | MAOACYP2E1 | |
| SCHEMBL3046131 | 0.78 | MAOA (0.54) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3035256 | 0.74 | MAOA (0.64) | MAOACYP2E1MAOBHTR6LMNA | |
| SCHEMBL3039820 | 0.74 | MAOA (0.38) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL3033105 | 0.69 | TSHR (0.38) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL13515915 | 0.69 | TSHR (0.38) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL3041933 | 0.69 | TSHR (0.38) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL14334647 | 0.67 | HTR6 (0.62) | MAOAMAOBHTR6 | |
| SCHEMBL3038917 | 0.67 | MAOA (0.48) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL3038659 | 0.67 | MAOA (0.45) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | MAOA 957/4885CYP2E1 852/4885MAOB 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.